Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy
NCT00001212Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 1986
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide and cyclosporine in Membranous Lupus Nephritis (MLN) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Time to complete or partial remission of proteinuria at 1 year. Started Nov 1986; status: completed.
02
Drugs
cyclophosphamidecyclosporine
03
Conditions
Membranous Lupus Nephritis (MLN)
Beyond the preview
Go deeper on NCT00001212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001212.